What dual classification does Valsartan/Sacubitril fall under?

Valsartan/Sacubitril is classified as an Angiotensin II Receptor Antagonist and a Neprilysin Inhibitor. This combination works synergistically to enhance cardiac output and reduce the symptoms of heart failure.

Valsartan, which is the angiotensin II receptor antagonist component, helps to block the effects of angiotensin II, a hormone that constricts blood vessels and leads to increased blood pressure. By blocking this hormone, Valsartan contributes to vasodilation and lowering blood pressure.

Sacubitril, on the other hand, inhibits neprilysin, an enzyme responsible for the degradation of natriuretic peptides and other vasoactive substances. By inhibiting neprilysin, Sacubitril increases the levels of these beneficial peptides, which promote vasodilation, natriuresis, and diuresis, further helping in reducing cardiovascular strain.

The dual action of blocking angiotensin II receptors while increasing the availability of natriuretic peptides leads to a more comprehensive approach in treating conditions like heart failure, providing better outcomes for patients. This understanding of the mechanism of action highlights the distinctive nature of this combination therapy.